||EPS - Basic
||Market Cap (m)
Ascribe Share Discussion Threads
Showing 1 to 12 of 25 messages
Chat Pages: 1
|It was quiet till you woke up Flop. Now everyone will join the cult...|
|Different strategy as said before; more like a special sits instutional approach...
OK here's the list:
AFR AEX BAO BHR BMR DPL EML (just doubled up) FDI KDD GEM JLP (out of SLV) LONR MWA URU RRL VOG
The whole parcel currently up £1.3k for £165k invested, mainly due to relative recency of several transactions, profit taking and net of massive dividends from EML and URU.
|ffs rp., cant you find a quieter fred? ;-)|
|I have the riskiest potash exposure in SXX, because I've been convinced for nearly a year that Potash is the next gold. I expect you guys with FX exposure can buy Mosaic or Potash Corp.
Meanwhile, can I reiterate my conviction that you should look at any realistic, undervalued Africa met/min/oil/precious stones play for the long haul because it's probably months at most before the Chinese hoover starts to suck. Once there's a significant acquisition they'll be taken out like 9 pins for all the valid reasons why Mac doesn't play AIM...the whole bloody market is massively oversold.
Imagine if either your favourite African plays got taken out and/or found committed development and production capital....Look at the takeout price VED is paying for Cairn; and the price DNX is demanding from KNOC...
so here's an interesting post on the theme that I found elsewhere:
And yes I do hold RRL and separately AFR is my favourite Chinese target in Africa (plus jv opportunities with LONR...)|
|The big message from the BHP/Potash, KNOC/DNX and VED/Cairn bids is that M&A is BACK!!! This is a game-changer in the markets and the consequent consolidation totally fits with the deflationary outlook...Make hay while the sun shines; analysts and journalists are utterly predicatble - they'll be running the rule over the same sectors/similar stocks and also looking for past bids/stories and potential vulnerability/undervalue. Many mining and oil/gas stocks have in common that the value is in the ground, not the balance sheet. The Chinese won't miss the significance of this when allied to resource scarcity (e,g, zinc, which is also carbon friendly, viz my purchase of HER) and their gambling nature.
I repeat my prediction - the Chinese economy will be the biggest in the world in 2020; for the first time in my lifetime US is not the global engine of growth...|
|If you've been following the Potash developments, this is relevant to one of my sub-strategies re Agribusiness. In 10 years the global food need will double. So far, I have SXX (for potash and salt plus the green play), EAH (pest control in cheap high volume animals, viz pigs) and AGAP (agri futures). I would have bought Potash Corp and Mosaic as well if I dealt in dollars. Big play. Increase your exposure to Agribus (but Not NFD...)|
|ticker now changed...see
any info...thoughts...background greatly appreciated on this new stock
|Ive bought a few for a 3 year view, to take advantage of 60% rebate from the tax man...|
|Now why would Chris Moore the founder of Torex put £2.5m for a 13% stake in a company which is a direct competitor to Isoft, the company he sold to...I wonder?|
|Not getting off to a good start. Overvalued on admission. Can't even get their own ticker right!|
|Ascribe, the health IT group focusing on medicines management, today announces
the commencement of dealings of its Ordinary Shares on the AIM market (AIM) of
the London Stock Exchange. Seymour Pierce is acting as Nominated Adviser and as
Broker to the Company. The stock market EPIC will be ASP.L.
Total number of New Ordinary Shares being placed on behalf of the Company 27,777,778
Number of Sale Shares being placed on behalf of Selling Shareholders 2,777,778
Total number of Ordinary Shares being placed 30,555,556
Issue Price 18p
Number of Ordinary Shares in issue immediately following Admission 103,441,732
Percentage of the Enlarged Share Capital being placed 29.5%
Market capitalisation at the Issue Price #18.6 million
Gross proceeds of the Placing receivable by the Company #5 million
Reasons for Admission to AIM and use of proceeds of the Placing
The proceeds of the Placing of the New Ordinary Shares, expected to amount to #5
million (before expenses) will be used by the Company, amongst other things, to
fund the acquisition of Protechnic Exeter Limited.
Stephen Critchlow, Chairman and Chief Executive of Ascribe, said: "We are
delighted that the flotation of the Company has been completed successfully.
The listing will enable us to take Ascribe to the next stage of its development
and maximise any acquisition opportunities for the Company within the
international healthcare market. Our strategy is to build on our position in
the medicines management market through organic growth and through a number of
acquisitions of profitable companies, such as Protechnic Exeter, which offer
complementary established systems to customers needing a medicines management
Chat Pages: 1